Rezvilutamide for high-risk prostate cancer after surgery
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new pill, Rezvilutamide, for men with prostate cancer that was removed by surgery but has features that make it more likely to come back. It's an alternative for those who don't want or can't have radiation therapy after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- 18 years or older
- Your cancer was confirmed as prostate adenocarcinoma (the most common type) and you've had your prostate removed
- You are considered high-risk based on things like cancer at the edges of the removed tissue, the cancer was stage pT3 or pT4, cancer in lymph nodes, or a PSA of 20 or higher before surgery
- You do not want radiation therapy after surgery
- Your PSA level is very low (under 0.1) at screening, meaning the surgery likely removed all visible cancer
- You are otherwise healthy enough (able to do daily activities, no serious heart or other conditions)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a combination of hormone treatments before surgery can improve outcomes for men with prostate cancer that has spread locally or to a few bone spots. It uses genetic testing to match participants with the most effective treatment.
This trial tests if a daily pill called Rezvilutamide can prevent prostate cancer from returning in men who had their prostate removed and are at high risk of recurrence. It is for men who cannot or choose not to have radiation therapy.
This Phase 2 study tests rezvilutamide in men whose prostate-specific antigen (PSA) starts rising again after the prostate has been removed. It aims to see whether this treatment can help prevent or slow cancer spread after surgery, especially in men without signs of spread on scans.
This study tests whether giving rezvilutamide before surgery can help treat high-risk prostate cancer. It may improve surgery outcomes and reduce the chance of cancer coming back.
This trial tests a new drug, rezvilutamide, combined with standard hormone therapy for men with prostate cancer that has spread but still responds to hormone treatment. The goal is to see if this drug helps control the cancer longer than the usual treatment alone.
This trial tests whether adding a new oral hormone blocker (rezvilutamide) to standard salvage radiation and hormone therapy can better control prostate cancer that has come back (rising PSA) after surgery.
Hear when a new Prostate Cancer (Adenocarcinoma) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.